

# Richard J Honeywell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2114985/publications.pdf>

Version: 2024-02-01

37  
papers

774  
citations

567281

15  
h-index

526287

27  
g-index

37  
all docs

37  
docs citations

37  
times ranked

1451  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 1595-1602.	7.0	12
2	The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100371.	1.7	4
3	Carboplatin Dosing in Children Using Estimated Glomerular Filtration Rate: Equation Matters. <i>Cancers</i> , 2021, 13, 5963.	3.7	3
4	Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. <i>Cancers</i> , 2020, 12, 3322.	3.7	10
5	<sup>11</sup> C-sorafenib and <sup>15</sup> O-H <sub>2</sub> O PET for early evaluation of sorafenib therapy. <i>Journal of Nuclear Medicine</i> , 2020, 62, jnumed.120.251611.	5.0	0
6	Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function. <i>Journal of Cellular Physiology</i> , 2020, 235, 8085-8097.	4.1	7
7	Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome. <i>Cancers</i> , 2020, 12, 330.	3.7	11
8	Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3619.	4.1	19
9	Breastfeeding during R-CHOP chemotherapy: please abstain!. <i>European Journal of Cancer</i> , 2019, 119, 107-111.	2.8	10
10	Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 411-418.	1.6	16
11	Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1213-1214.	2.4	7
12	RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 311-322.	4.1	17
13	Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab. <i>Angiogenesis</i> , 2018, 21, 325-334.	7.2	20
14	DNA methyltransferases expression in normal tissues and various human cancer cell lines, xenografts and tumors.. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2018, 37, 696-708.	1.1	19
15	Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study. <i>British Journal of Cancer</i> , 2018, 119, 1326-1331.	6.4	15
16	Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. <i>Cancers</i> , 2018, 10, 503.	3.7	44
17	Subcellular localization of several structurally different tyrosine kinase inhibitors. <i>ADMET and DMPK</i> , 2018, 6, 258-266.	2.1	3
18	Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24078-e24078.	1.6	0

#	ARTICLE	IF	CITATIONS
19	A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 2591-2591.	1.6	1
20	Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: A phase I exposure escalation study.. Journal of Clinical Oncology, 2017, 35, TPS2620-TPS2620.	1.6	0
21	Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth. Journal of Experimental and Clinical Cancer Research, 2016, 35, 138.	8.6	17
22	Sensitive liquid chromatography mass spectrometry (LC-MS) assay reveals novel insights on DNA methylation and incorporation of gemcitabine, its metabolite difluorodeoxyuridine, deoxyuridine, and RX-3117 into DNA. Nucleosides, Nucleotides and Nucleic Acids, 2016, 35, 652-662.	1.1	4
23	Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Expert Review of Anticancer Therapy, 2016, 16, 147-157.	2.4	33
24	Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR. Oncotarget, 2016, 7, 5240-5257.	1.8	23
25	Transport of six tyrosine kinase inhibitors: active or passive?. ADMET and DMPK, 2016, 4, 23.	2.1	7
26	Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer (AEGC).. Journal of Clinical Oncology, 2016, 34, e15555-e15555.	1.6	0
27	Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction. Cancer Medicine, 2015, 4, 1003-1015.	2.8	29
28	Adaptation of a human gut epithelial model in relation to the assessment of clinical pharmacokinetic parameters for selected tyrosine kinase inhibitors. ADMET and DMPK, 2015, 3, .	2.1	3
29	Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 703-717.	3.3	18
30	Inhibition of thymidylate synthase by 2â€²,2â€²-difluoro-2â€²-deoxycytidine (Gemcitabine) and its metabolite 2â€²,2â€²-difluoro-2â€²-deoxyuridine. International Journal of Biochemistry and Cell Biology, 2015, 60, 73-81.	2.8	41
31	Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cellular Oncology (Dordrecht), 2015, 38, 119-129.	4.4	46
32	A phase 1 study of weekly high dose sunitinib in patients with advanced solid tumors: Early signs of activity in non-RCC tumor types.. Journal of Clinical Oncology, 2015, 33, e13550-e13550.	1.6	0
33	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. SpringerPlus, 2014, 3, 732.	1.2	23
34	Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience, 2014, 1, 844-853.	2.2	26
35	Tumor, skin, and plasma concentrations of protein kinase inhibitors (PKIs) in patients with advanced cancer.. Journal of Clinical Oncology, 2013, 31, 11087-11087.	1.6	2
36	Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance. Clinical Cancer Research, 2011, 17, 7337-7346.	7.0	275

#	ARTICLE	IF	CITATIONS
37	Determination of the Phosphorylated Metabolites of Gemcitabine and of Difluorodeoxyuridine by LCMSMS. Nucleosides, Nucleotides and Nucleic Acids, 2011, 30, 1203-1213.	1.1	9